Results 201 to 210 of about 419,324 (239)
Some of the next articles are maybe not open access.

Calcium-Agonists

Journal of Molecular and Cellular Cardiology, 1986
In contrast to nifedipine-like calcium antagonists, calcium agonistic 1,4-dihydropyridines have vasoconstricting and positive inotropic properties. BAY K 8644 has become the prototype of this new class. Its enantiomers show opposite effects on the calcium channel: one acts as a calcium agonist with the pharmacological profile of the racemic compound ...
M, Bechem, M, Schramm
openaire   +2 more sources

Dopamine Agonists

Seminars in Neurology, 2001
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire   +2 more sources

TAAR Agonists

Cellular and Molecular Neurobiology, 2019
Trace amine-associated receptors (TAARs) are a family of G protein-coupled receptors (GPCRs) that are evolutionarily conserved in vertebrates. The first discovered TAAR1 is mainly expressed in the brain, and is able to detect low abundant trace amines.
Zhengrong Xu, Qian Li
openaire   +2 more sources

A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists

2023
The Gs-coupled A2A adenosine receptor (A2AAR) has been explored extensively as a pharmaceutical target, which has led to numerous clinical trials. However, only one selective A2AAR agonist (regadenoson, Lexiscan) and one selective A2AAR antagonist (istradefylline, Nouriast) have been approved by the FDA, as a pharmacological agent for myocardial ...
Kenneth A, Jacobson   +2 more
openaire   +2 more sources

Agonists, partial agonists, antagonists, inverse agonists and agonist/antagonists?

Trends in Pharmacological Sciences, 1987
The label placed on a drug influences its ultimate use. But interpretation ofin-vivo data has complicated the simple receptor theory of agonists and antagonists for certain classes of drugs.Terry Kenakin argues that clarification of such data — described in an extremely complex system — at a molecular level, will either obviate the need for terms such ...
openaire   +1 more source

Home - About - Disclaimer - Privacy